Objective: To clarify the possible associations of  levodopa / benserazidehydrochloride usage and  skin rashes.

Background:   Levodopa/benserazide hydrochloride   is one of the best dopaminergic drug used for Parkinson’s disease. In Turkey,  levodopa/benserazide  (L/B) is available in three doses: 100/25, 200/50 and 100/25 HBS (slow-release). Skin rashes has been reported with  another dopaminergic drug  (carbidopa/levodopa ) but not with  L/B. We report two patients with rashes resulting from  L/B  formulation . Prompt cessation of the treatment led to resolution of the rash over two to four weeks.  Within this context we phoned  our patients receiving  L/B monotherapy and asked for existence of rashes.

Methods: 32 patients with Parkinson’s disease receiving levodopa / benserazidehydrochloride and monotherapyincluded in this study. A clinical questionnaire used to determine occurrance of rashes due to L/B monotherapy.

Results: In our study, there are only two patients having rashes . Statistically the incidence of rash was very lower in this 32 L/B monotherapy patients (p<0.005) . Prompt of the treatment or switching to other drug can be effective for this situation.

Conclusions: Rashes with levodopatherapy are very rare.In the literature there are two case report having rashes.

References: 1.Chou, K L. MD; Stacy, M A. MD .Skin rash associated with Sinemet does not equal levodopa allergy.Neurology Issue: Volume 68(13), 27 March 2007, pp 1078-­1079  

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/how-usual-is-skin-rashes-during-treatment-with-levodopa-benserazide-hydrochloride/